Luděk Pour

3.9k total citations
109 papers, 1.1k citations indexed

About

Luděk Pour is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Luděk Pour has authored 109 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Hematology, 62 papers in Molecular Biology and 43 papers in Oncology. Recurrent topics in Luděk Pour's work include Multiple Myeloma Research and Treatments (92 papers), Protein Degradation and Inhibitors (31 papers) and Peptidase Inhibition and Analysis (23 papers). Luděk Pour is often cited by papers focused on Multiple Myeloma Research and Treatments (92 papers), Protein Degradation and Inhibitors (31 papers) and Peptidase Inhibition and Analysis (23 papers). Luděk Pour collaborates with scholars based in Czechia, United States and Spain. Luděk Pour's co-authors include Roman Hájek, Sabina Ševčı́ková, Martin Štork, Marta Krejčí, Martina Almáši, Tomáš Jelı́nek, Jiří Minařík, Zdeněk Adam, Petr Kuglík and Viera Sandecká and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Luděk Pour

100 papers receiving 1.1k citations

Peers

Countries citing papers authored by Luděk Pour

Since Specialization

Citations

This map shows the geographic impact of Luděk Pour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luděk Pour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luděk Pour more than expected).

Fields of papers citing papers by Luděk Pour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luděk Pour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luděk Pour. The network helps show where Luděk Pour may publish in the future.

Co-authorship network of co-authors of Luděk Pour

This figure shows the co-authorship network connecting the top 25 collaborators of Luděk Pour. A scholar is included among the top collaborators of Luděk Pour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luděk Pour. Luděk Pour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detection of early relapse in multiple myeloma patients 2025 ·Cell Division ·(unknown), (unknown), (unknown), (unknown), (unknown), Lenka Radová, Sabina Ševčı́ková, Marie Jarošová, Josef Havel, Luděk Pour	4
2	An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma 2024 ·European Journal Of Haematology ·Prashant Kapoor, Nitya Nathwani, Tomáš Jelı́nek, Luděk Pour, Aurore Perrot, Meletios Α. Dimopoulos, Shang‐Yi Huang, Ivan Špıčka, Saurabh Chhabra, Eben I. Lichtman, María‐Victoria Mateos, (unknown), Liang Zhao, (unknown), Sandrine Macé, Helgi van de Velde, Paul G. Richardson	1
3	Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry 2023 ·Journal of the American Society for Mass Spectrometry ·(unknown), (unknown), (unknown), Jana Gregorová, (unknown), (unknown), Martina Almáši, Luděk Pour, Martin Štork, Josef Havel, Sabina Ševčı́ková, Petr Vaňhara	4
4	Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis 2023 ·Annals of Hematology ·Martin Štork, Ivan Špıčka, Jakub Radocha, Jiří Minařík, Tomáš Jelı́nek, Alexandra Jungová, (unknown), Lenka Pospíšilová, František Sedlák, Jan Štraub, Tomáš Pika, (unknown), (unknown), (unknown), Sabina Ševčı́ková, Vladimír Maisnar, Roman Hájek, Luděk Pour	6
5	Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang‐Ki Min, Danielle Leão Cordeiro de Farias, Alexander Vorog, Richard Labotka, Bingxia Wang, (unknown), Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios Α. Dimopoulos	2
6	Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas 2022 ·Biomedicines ·Martin Štork, Sabina Ševčı́ková, Tomáš Jelı́nek, Jiří Minařík, Jakub Radocha, Tomáš Pika, Lenka Pospíšilová, Ivan Špıčka, Jan Štraub, (unknown), Alexandra Jungová, (unknown), Viera Sandecká, Vladimír Maisnar, Roman Hájek, Luděk Pour	2
7	Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Vladimír Maisnar, Luděk Pour, Ivan Špıčka, Tomáš Jelı́nek, Jiří Minařík, Alexandra Jungová, Martin Štork, Jan Štraub, Jakub Radocha, Tomáš Pika, Lenka Pospíšilová, Sandhya Nair, (unknown), Roman Hájek	4
8	Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy 2022 ·Cancers ·Jiří Minařík, Jakub Radocha, Alexandra Jungová, Jan Štraub, Tomáš Jelı́nek, Tomáš Pika, Luděk Pour, (unknown), (unknown), Lenka Pospíšilová, (unknown), (unknown), Pavel Jindra, Ivan Špıčka, (unknown), Martin Štork, Jaroslav Bačovský, Vladimír Maisnar, Roman Hájek	5
9	Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma 2022 ·International Journal of Molecular Sciences ·(unknown), Jana Gregorová, (unknown), (unknown), Lenka Radová, Lenka Pospíšilová, Martina Almáši, Martin Štork, (unknown), Jiří Minařík, (unknown), Tomáš Jelı́nek, Roman Hájek, Luděk Pour, Lucie Říhová, Sabina Ševčı́ková	4
10	Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma 2022 ·HemaSphere ·Pieter Sonneveld, Sonja Zweegman, Michèle Cavo, Kazem Nasserinejad, Annemiek Broijl, (unknown), Luděk Pour, Sandra Croockewit, Paolo Corradini, Francesca Patriarca, (unknown), (unknown), Gerard M.J. Bos, Roman Hájek, Maria Teresa Petrucci, Paula F. Ypma, (unknown), Monique C. Minnema, Mario Boccadoro	12
11	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients 2021 ·Biomedicines ·(unknown), (unknown), Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, (unknown), Martin Štork, Luděk Pour, Sabina Ševčı́ková	5
12	The Correlation between NRF2Antioxidant Gene Expression and Sperm Quality in Asthenoteratozoospermia Men 2020 ·(unknown), Luděk Pour, (unknown), (unknown)	0
13	Plasma Cell Leukemia – the Forgotten Disease 2019 ·Klinicka onkologie ·(unknown), (unknown), Renata Bezděková, (unknown), Marie Jarošová, Zdeněk Adam, Marta Krejčí, Luděk Pour, Sabina Ševčı́ková	0
14	Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients 2018 ·Neoplasma ·Martin Štork, (unknown), Zdeněk Adam, Marta Krejčí, Viera Sandecká, Zdeněk Král, Lucie Brožová, (unknown), Luděk Pour	4
15	Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma 2015 ·PLoS ONE ·Lenka Bešše, Lenka Sedlaříková, Fedor Kryukov, Jana Nekvindová, Lenka Radová, Ondřej Slabý, Petr Kuglík, Martina Almáši, Miroslav Penka, Marta Krejčí, Zdeněk Adam, Luděk Pour, Sabina Ševčı́ková, Roman Hájek	18
16	Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases 2012 ·Acta Oncologica ·Zdeněk Adam, Petr Szturz, Jiří Vaníček, Mojmír Moulis, Luděk Pour, Marta Krejčí, Roman Hájek, Jiřı́ Mayer	10
17	Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation 2010 ·Neoplasma ·Henrieta Grešlíková, (unknown), (unknown), Pavel Němec, Alexandra Oltová, (unknown), (unknown), Jan Smetana, Luděk Pour, (unknown), Marta Krejčí, Tomáš Büchler, (unknown), Roman Hájek, Petr Kuglík	15
18	Evaluation of HGF and Endostatin in the bone marrow of patients with multiple myeloma and the effect of peripheral blood admixture 2009 ·Luděk Pour, (unknown), Tomáš Büchler, Zdeněk Adam, Miroslav Penka, Jiří Vorlíček, Roman Hájek	1
19	[Monoclonal gammopathies of undetermined significance]. 2008 ·PubMed ·(unknown), Vladimír Maisnar, Luděk Pour, Jakub Radocha, Roman Hájek	1
20	Evaluation of hepatocyte growth factor and endostatin in thebone marrow of patients with multiple myeloma and the effect ofperipheral blood admixture 2005 ·Luděk Pour, (unknown), Tomáš Büchler, Miroslav Penka, Jiří Vorlíček, Roman Hájek	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact